Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist

Minerva Medica

Volumn 102, Issue 2, 2011, Pages 141-147

  Conigliaro, R ^a   Drago, V ^b,c   Foster, P S ^d   Schievano, C ^e   Di Marzo, V ^f  

^a Operative Unity of Neurology   (Italy)

^b UNIVERSITY OF FLORIDA   (United States)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

^d MIDDLE TENNESSEE STATE UNIVERSITY   (United States)

^e UNIVERSITY OF PADOVA   (Italy)

^f CNR   (Italy)

Author keywords

Carpal tunnel syndrome; Motor distal latency; Pain; Palmitoylethanolamide; Peripheral neuropathy

Indexed keywords

NORMAST; PALMIDROL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELECTRONEUROGRAPHY; FEMALE; HUMAN; LATENT PERIOD; MALE; NEUROLOGIC EXAMINATION; NEUROPATHY; TINEL TEST;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARPAL TUNNEL SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; PALMITIC ACIDS;

EID: 79957659495     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosen I. Prevalence of Carpal Tunnel Syndrome in a general population. JAMA 1999;281:153-8. (Pubitemid 29323805)
2. Evans SM. Manual of neurologic practice. RW Evans. Philadelphia, PA: Saunders; 2003.
3. Gelfman R, Melton LJ3rd, Yawn BP, Wollan PC, Amadio PC, Stevens JC. Long-term trends in carpal tunnel syndrome. Neurology 2009;72:33-41.
4. AAN, AAEM, AAPMR. Practice parameter for electro-diagnostic studies in carpal tunnel syndrome (summary statement). Neurology 1993;43:2404-5.
5. Jack DB. Aliamides: a new approach to the treatment of inflammation. Drug News & Perspective 1996;9:93-8. (Pubitemid 26153190)
6. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 2004;279:5298-305. (Pubitemid 38220550)
7. Mazzari S, Cannella R, Petrelli L, Marcolongo G, Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by modulating mast cell activation. Eur J Pharmacol 1996;300:227-36.
8. Costa B, Conti S, Giagnoni G, Colleoni M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol 2002;137:413-20. (Pubitemid 35221894)
9. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 2007;173:21-30.
10. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 2008;139:541-50.
11. Jaggar SI, Hasnie FS, Sellatuary S, Rice AS. The anti hyperalgesic actions of the cannabinoid anandamide and the semantic inflammatory pain. Pain 1998;76:189-99.
12. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-81. (Pubitemid 28335039)
13. Lombardi G, Miglio G, Varsaldi F, Minassi A, Appendino G. Oxyhomologation of the amide bond potentiates neuroprotective effects of the endolipid N-palmitoylethanolamine. J Pharmacol Exp Ther 2007;320:599-606. (Pubitemid 46147939)
14. Sheerin AH, Zhang X, Saucier DM, Corcoran ME. Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. Epilepsia 2004;45:1184-8. (Pubitemid 39350330)
15. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 2007;52:415-22. (Pubitemid 46127787)
16. Helyes Z, Nemeth J, Than M, Bolcskei K, Pinter E, Szolcsanyi J. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sciences 2003:73:2345-53. (Pubitemid 36980829)
17. Padua L, Lo Monaco M, Gregori B, Valente EM, Padua R, Tonali P. Neurophysiological classification and sensitivity in 500 carpal tunnel syndrome hands. Acta Neurol Scand 1997;96:211-7. (Pubitemid 27402488)
18. Masek K, Perlík F, Klíma J, Kahlich R. Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur J Clin Pharmacol 1974;6:415-9.
19. Kahlich R, Klíma J, Cihla F, Franková V, Masek K, Rosicky M et al. Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J Hyg Epidemiol Microbiol Immunol 1979;23:11-24. (Pubitemid 9256928)
20. Aroori S, Spence RA. Carpal tunnel syndrome. Ulster Med J 2008;77:6-17. (Pubitemid 351148700)
21. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 1993;39:C145-7.
22. Lo Verme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life Sciences 2005;77:1685-98.
23. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995;92:3376-80.
24. Cerrato S, Brazis P, Delia Valle MF, Miolo A, Puigdemont A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD(2) and TNFalpha release from canine skin mast cells. Vet Immunol Immunopathol 2010;133:9-15.
25. Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P et al. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther 2008;326:12-23. (Pubitemid 351872139)
26. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 2007;150:766-81. (Pubitemid 46440215)
27. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, Docagne F, Hagen C, Bisogno T et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis 2009;33:57-71.
28. Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R et al. Involvement of the cannabimimetic compound, N palmitoylethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data and first human studies. Neuropharmacology 2005;48:1154-63.
29. Degenhardt BF, Darmani NA, Johnson JC, Towns LC, Rhodes DC, Trinh C et al. Role of osteopathic manipulative treatment in altering pain biomarkers: a pilot study. J Am Osteopath Assoc 2007;107:38.